Instructions for Authors
December 22

Editorial Policy

General
Human Cell is published in partnership with the Japan Human Cell Society (http://jhcs.kenkyukai.jp/information/). The journal serves as a forum for international research on all aspects of human cell biology, animal cell biology in the field of regenerative medicine, and other related disciplines, in addition to showcasing the research activities of the society. Research Articles, Cell Lines, Rapid Communications, Reviews, and Letter to the Editor are welcome via the online submission system.

Publication Fees
Publication fees are required for both members and non-members. The charge per page is 15,000 yen. Accepted articles will not be published until the publication fee has been received.

Authors will be invoiced by Gakkai Kenkyuukai corporation (English service name: Aca-Med) on behalf of the society. You can choose credit card payment or bank transfer (bank transfer only within Japan). The payment request email from Aca-Med will serve as an invoice, and the statement from your credit card company or bank will serve as a receipt.

Certification Form
The Certification Form should be signed and submitted with the manuscript. The author(s) should attest that: no part of the work described has been published before; that the work is not under consideration for publication anywhere else; that its publication has been approved by all co-authors, if any, and when the manuscript is accepted for publication, the author(s) agree(s) to automatic transfer of the copyright to the society and the Publisher and that the manuscript, or its parts, will not be published elsewhere subsequently in any language without the consent of the copyright holders.


Editorial Review and Acceptance
The acceptance criteria for all papers are the quality and originality of the research and its significance to our readership. Except where otherwise stated, manuscripts are single-blind peer-reviewed by two anonymous reviewers and the Editor. Final acceptance or rejection rests with the Editorial Board, who reserves the right to refuse any material for publication.

Manuscripts should be written so that they are intelligible to the professional reader who is not a specialist in the particular field. They should be written in a clear, concise, direct style. Where contributions are judged as acceptable for publication on the basis of scientific content, the Editor and the Publisher reserve the right to modify typescripts to eliminate ambiguity and repetition and improve communication between author and reader. If extensive alterations are required, the manuscript will be returned to the author for revision.

A paper can be rejected without undergoing the peer-review process if the Editor determines that the content is inappropriate for the journal. Authors usually receive the editorial decision within 6 weeks of the manuscript’s arrival at the Editorial Office.

The Japan Human Cell Society

Manuscript Submission

Manuscript Submission
Submission of a manuscript implies: that the work described has not been published before; that it is not under consideration for publication anywhere else; that its publication has been approved by all co-authors, if any, as well as by the responsible authorities – tacitly or explicitly – at the institute where the work has been carried out. The Publisher will not be held legally responsible should there be any claims for compensation.

Permissions
Authors wishing to include figures, tables, or text passages that have already been published elsewhere are required to obtain permission from the copyright owner(s) for both the print and online format and to include evidence that such permission has been granted when submitting their papers. Any material received without such evidence will be assumed to originate from the authors.

Online Submission
Authors should submit their manuscripts online. Electronic submission substantially reduces the editorial processing and reviewing times and shortens overall publication times. Please follow the hyperlink “Submit online” on the right and upload all of your manuscript files following the instructions given on the screen.

The Certification Form should also be uploaded.

Editorial Office
Hiroaki Kataoka (Editor-in-Chief)
Human Cell Editorial Office
c/o Department of Pathology, Faculty of Medicine
University of Miyazaki
5200 Kihara, Kiyotake, Miyazaki 889-1692 Japan
Fax: +81-985856003
Tel: +81-985852809
e-mail: edit_humcell@med.miyazaki-u.ac.jp

Title Page

Title Page
The title page should include:
- The name(s) of the author(s)
- A concise and informative title
- The affiliation(s) and address(es) of the author(s)
- The e-mail address, telephone and fax numbers of the corresponding author

Abstract
All articles except Letters to the Editor must have a brief
abstract that states in 250 or fewer words the purpose, basic procedures, main findings and principal conclusions of the study. The abstract should not contain any undefined abbreviations or unspecified references.

**Keywords**
Please provide 5 keywords that can be used for indexing purposes.

**Acknowledgments**
Acknowledgments of people, grants, funds, etc. should be placed in a separate section before the reference list. The names of funding organizations should be written in full.

**Conflict of Interest**
All benefits in any form from a commercial party related directly or indirectly to the subject of the manuscript or any of the authors must be acknowledged. For each source of funds, both the research funder and the grant number should be given. This note should be added in a separate section before the reference list. If no conflict exists, authors should state: The authors declare that they have no conflict of interest.

**Text**

**Word Length**
The length of an article (excluding references, figure legends, tables and appendices) should not exceed 3600 words. Letters to the Editor should not exceed 1000 words, and no more than 10 references may be cited.

**Spelling**
The journal uses American spelling and authors should therefore follow the latest edition of the Merriam–Webster’s Collegiate Dictionary.

**Text Formatting**
Manuscripts should be submitted in Word.
• Use a normal, plain font (e.g., 10-point Times Roman) for text.
• Use the automatic page-numbering function to number the pages.
• Do not use field functions.
• Use tab stops or other commands for indents, not the space bar.
• Use the table function, not spreadsheets, to make tables.
• Use the equation editor or MathType for equations. Note: If you use Word 2007, do not create the equations with the default equation editor but use the Microsoft equation editor or MathType instead.
• Save your file in doc or docx format.

**Headings**
Please use no more than three levels of displayed headings.

**Abbreviations**
Abbreviations should be defined at first mention and used consistently thereafter.

**Footnotes**
Footnotes can be used to give additional information, which may include the citation of a reference included in the reference list. They should not consist solely of a reference citation, and they should never include the bibliographic details of a reference. They should also not contain any figures or tables. Footnotes to the text are numbered consecutively. Footnotes to the title or the authors of the article are not given reference symbols. Always use footnotes instead of endnotes.

**Terminology**
• Always use internationally accepted signs and symbols for units (SI units). Please go to the Bureau International des Poids et Mesures (BIPM) website at http://www.bipm.fr for more information about SI units.
• **Nomenclature**: Insofar as possible, authors should use systematic names similar to those used by Chemical Abstract Service or IUPAC. Standard genetic nomenclature should be used. For further information, including relevant websites, authors should refer to the genetic nomenclature guide in Trends in Genetics (Elsevier Science, 1998).
• **Genus and species names** should be in italics. Upon its first use in the title, abstract and text, the common name of a species should be followed by the scientific name (genus, species and authority) in parentheses. However, for well-known species, the scientific name may be omitted from the article title. If no common name exists in English, only the scientific name should be used.
• **Generic names** of drugs and pesticides are preferred; if trade names are used, the generic name should be given at first mention.
• **Nucleotide sequence data** can be submitted in electronic form to any of the three major collaborative databases: DDBJ, EMBL or GenBank. It is only necessary to submit to one database as data are exchanged between DDBJ, EMBL and GenBank on a daily basis. The suggested wording for referring to accession-number information is: “These sequence data have been submitted to the DDBJ/EMBL/GenBank databases under accession number U12345.”

Addresses are as follows:
DNA Data Bank of Japan (DDBJ) http://www.ddbj.nig.ac.jp
EMBL Nucleotide Sequence Submissions http://www.ebi.ac.uk

**References**

**Citations**
Reference citations in the text should be identified by numbers in square brackets. Some examples:
1. Negotiation research spans many disciplines [3].
2. This result was later contradicted by Becker and Seligman [5].
3. This effect has been widely studied [1-3, 7].

**Reference list**
The list of references should include only works that are cited in the text and that have been published or accepted for publication. Personal communications and unpublished works should be mentioned only in the text. Do not use footnotes or endnotes as a substitute for a reference list.
The entries in the list should be numbered consecutively.
In the reference list, give the names of all authors when there
are six or fewer; when seven or more, list the first three
followed by et al.

- **Journal article**
- **Article by DOI**
  Slifka MK, Whitton JL. Clinical implications of dysregulated
- **Book**
  Blenkinsopp A, Paxton P. Symptoms in the pharmacy: a guide
to the management of common illness. 3rd ed. Oxford:
Blackwell Science; 1998.
- **Book chapter**
  Wyllie AH, Kerr JFR, Currie AR. Cell death: the significance
251–306.
- **Online document**
  Doe J. Title of subordinate document. In: The dictionary of
substances and their effects. Royal Society of Chemistry.
1999.
  http://www.rsc.org/dose/title of subordinate document.

Always use the standard abbreviation of a journal’s name
according to the ISSN List of Title Word Abbreviations, at
http://www.issn.org/2-22661-LTWA-online.php

For authors using EndNote, Springer provides an output style
that supports the formatting of in-text citations and the
reference list. Please refer to HTML version of Instructions
for Authors on the journal homepage.

[Link to the journal homepage](#)

**Tables**
- All tables are to be numbered using Arabic numerals.
- Tables should always be cited in the text in consecutive
numerical order.
  - For each table, please supply a table title explaining the
  components of the table.
  - Identify any previously published material by giving the
  original source in the form of a reference at the end of the
  table title.
  - Footnotes to tables should be indicated by superscript
  lowercase letters (or asterisks for significance values and
  other statistical data) and included beneath the table body.

**Artwork**

**Electronic Figure Submission**
- Supply all figures electronically.
- Indicate what graphics program was used to create the
  artwork.
  - For vector graphics, the preferred format is EPS; for
  halftones, please use TIFF format. MS Office files are also
  acceptable.
  - Vector graphics containing fonts must have the fonts
  embedded in the files.
- Name your figure files with "Fig" and the figure number,
  e.g., Fig1.eps.

**Line Art**
- Definition: Black and white graphic with no shading.
- Do not use faint lines and/or lettering and check that all lines
  and lettering within the figures are legible at final size.
- All lines should be at least 0.1 mm (0.3 pt) wide.
- Scanned line drawings and line drawings in bitmap format
  should have a minimum resolution of 1200 dpi.

**Halftone Art**
- Definition: Photographs, drawings, or paintings with fine
  shading, etc.
- If any magnification is used in the photographs, indicate this
  by using scale bars within the figures themselves.
- Halftones should have a minimum resolution of 300 dpi.

**Combination Art**
- Definition: a combination of halftone and line art, e.g.,
  halftones containing line drawing, extensive lettering, color
  diagrams, etc.
- Combination artwork should have a minimum resolution of
  600 dpi.

**Color Art**
- There is no charge for publication of color art.
- Color illustrations should be submitted as RGB (8 bits per
  channel).

**Figure Lettering**
- To add lettering, it is best to use Helvetica or Arial (sans serif
  fonts).
- Keep lettering consistently sized throughout your final-sized
  artwork, usually about 2–3 mm (8–12 pt).
- Variance of type size within an illustration should be
  minimal, e.g., do not use 8-pt type on an axis and 20-pt type
  for the axis label.
- Avoid effects such as shading, outline letters, etc.
- Do not include titles or captions in your illustrations.

**Figure Numbering**
- All figures are to be numbered using Arabic numerals.
- Figures should always be cited in the text in consecutive
  numerical order.
- Figure parts should be denoted by lowercase letters (a, b, c,
  etc.). If illustrations are supplied with uppercase labeling,
  lowercase letters will still be used in the figure captions and
  citations.
- If an appendix appears in your article/chapter and it contains
  one or more figures, continue the consecutive numbering of
  the main text. Do not number the appendix figures, "A1, A2,
  A3, etc." Figures in online appendices (Electronic
  Supplementary Material) should, however, be numbered
  separately.

**Figure Captions**
- Each figure should have a concise caption describing
  accurately what the figure depicts. Include the captions in the
  text file of the manuscript, not in the figure file.
- Figure captions begin with the term Fig. in bold type,
  followed by the figure number, also in bold type.
- No punctuation is to be included after the number, nor is any
In the figure caption, identify all elements found in the figure; and use boxes, circles, etc., as coordinate points in graphs.

- Identify previously published material by giving the original source in the form of a reference citation at the end of the figure caption.

**Figure Placement and Size**
- When preparing your figures, size figures to fit in the column width.
- Figures should be 39 mm, 84 mm, 129 mm, or 174 mm wide and not higher than 234 mm.
- The Publisher reserves the right to reduce or enlarge figures.

**Permissions**
If you include figures that have already been published elsewhere, you must obtain permission from the copyright owner(s) for both the print and online format. Please be aware that some publishers do not grant electronic rights for free and that Springer will not be able to refund any costs that may have occurred to receive these permissions. In such cases, material from other sources should be used.

**Accessibility**
In order to give people of all abilities and disabilities access to the content of your figures, please make sure that

- All figures have descriptive captions (vision-impaired users could then use a text-to-speech software or a text-to-Braille hardware)
- Patterns are used instead or in addition to colors for conveying information (color-blind users would then be able to distinguish the visual elements)
- Any figure lettering has a contrast ratio of at least 4.5:1.

**Electronic Supplementary Material**
Electronic supplementary material will be published in the online version only.

- Information that cannot be printed: animations, video clips, sound recordings
- Information that is more convenient in electronic form: sequences, spectral data, etc.
- Large original data, e.g. additional tables, illustrations, etc.

**Submission**
- Supply all supplementary material in standard file formats.
- Please include in each file the following information: article title, journal name, author names; affiliation and e-mail address of the corresponding author.
- To accommodate user downloads, please keep in mind that larger-sized files may require very long download times and that some users may experience other problems during downloading.

**Audio, Video, and Animations**
- Always use MPEG-1 (.mpg) format.

**Text and Presentations**
- Submit your material in PDF format; .doc or .ppt files are not suitable for long-term viability.
- A collection of figures may also be combined in a PDF file.

**Spreadsheets**
- Spreadsheets should be converted to PDF if no interaction with the data is intended.
- If readers are encouraged to make their own calculations, spreadsheets should be submitted as .xls files (MS Excel).

**Specialized Formats**
- Specialized formats such as .pdb (chemical), .wrl (VRML), .nb (Mathematica notebook), and .tex can also be supplied.

**Collecting Multiple Files**
- It is possible to collect multiple files in a .zip or .gz file.

**Numbering**
- If any supplementary material is supplied, the text must make specific mention of the material as a citation, similar to that of figures and tables.
- Refer to the supplementary files as “Online Resource”, e.g., "... as shown in the animation (Online Resource 3)", “... additional data are given in Online Resource 4”.
- Name the files consecutively, e.g. “ESM_3.mpg”, “ESM_4.pdf”.

**Captions**
- For each supplementary material, please supply a concise caption describing the content of the file.

**Processing of Supplementary Files**
- Electronic supplementary material will be published as received from the author without any conversion, editing, or reformatting.

**Accessibility**
In order to give people of all abilities and disabilities access to the content of your supplementary files, please make sure that

- The manuscript contains a descriptive caption for each supplementary material
- Video files do not contain anything that flashes more than three times per second (so that users prone to seizures caused by such effects are not put at risk)

**Ethical Responsibilities of Authors**
This journal is committed to upholding the integrity of the scientific record. As a member of the Committee on Publication Ethics (COPE) the journal will follow the COPE guidelines on how to deal with potential acts of misconduct. Authors should refrain from misrepresenting research results which could damage the trust in the journal, the professionalism of scientific authorship, and ultimately the entire scientific endeavour. Maintaining integrity of the research and its presentation can be achieved by following the rules of good scientific practice, which include:

- The manuscript has not been submitted to more than one journal for simultaneous consideration.
- The manuscript has not been published previously (partly or in full), unless the new work concerns an expansion of previous work (please provide transparency on the re-use of material to avoid the hint of text-recycling ("self-plagiarism")).
- A single study is not split up into several parts to increase the
quantity of submissions and submitted to various journals or to one journal over time (e.g. “salami-publishing”).
• No data have been fabricated or manipulated (including images) to support your conclusions
• No data, text, or theories by others are presented as if they were the author’s own (“plagiarism”). Proper acknowledgements to other works must be given (this includes material that is closely copied (near verbatim), summarized and/or paraphrased), quotation marks are used for verbatim copying of material, and permissions are secured for material that is copyrighted.

Important note: the journal may use software to screen for plagiarism.
• Consent to submit has been received explicitly from all co-authors, as well as from the responsible authorities - tacitly or explicitly - at the institute/organization where the work has been carried out, before the work is submitted.
• Authors whose names appear on the submission have contributed sufficiently to the scientific work and therefore share collective responsibility and accountability for the results.

In addition:
• Changes of authorship or in the order of authors are not accepted after acceptance of a manuscript.
• Requesting to add or delete authors at revision stage, proof stage, or after publication is a serious matter and may be considered when justifiably warranted. Justification for changes in authorship must be compelling and may be considered only after receipt of written approval from all authors and a convincing, detailed explanation about the role/deletion of the new/deleted author. In case of changes at revision stage, a letter must accompany the revised manuscript.
• In case of changes after acceptance or publication, the request and documentation must be sent via the Publisher to the Editor-in-Chief. In all cases, further documentation may be required to support your request. The decision on accepting the change rests with the Editor-in-Chief of the journal and may be turned down. Therefore authors are strongly advised to ensure the correct author group, corresponding author, and order of authors at submission.
• Upon request authors should be prepared to send relevant documentation or data in order to verify the validity of the results. This could be in the form of raw data, samples, records, etc.

If there is a suspicion of misconduct, the journal will carry out an investigation following the COPE guidelines. If, after investigation, the allegation seems to raise valid concerns, the accused author will be contacted and given an opportunity to address the issue. If misconduct has been established beyond reasonable doubt, this may result in the Editor-in-Chief’s implementation of the following measures, including, but not limited to:
• If the article is still under consideration, it may be rejected and returned to the author.
• If the article has already been published online, depending on the nature and severity of the infraction, either an erratum will be placed with the article or in severe cases complete retraction of the article will occur. The reason must be given in the published erratum or retraction note.
• The author’s institution may be informed.

Compliance with Ethical Standards
To ensure objectivity and transparency in research and to ensure that accepted principles of ethical and professional conduct have been followed, authors should include information regarding sources of funding, potential conflicts of interest (financial or non-financial), informed consent if the research involved human participants, and a statement on welfare of animals if the research involved animals.

Authors should include the following statements (if applicable) in a separate section entitled “Compliance with Ethical Standards” before the References when submitting a paper:
• Disclosure of potential conflicts of interest
• Research involving Human Participants and/or Animals
• Informed consent

Please note that standards could vary slightly per journal dependent on their peer review policies (i.e. double blind peer review) as well as per journal subject discipline. Before submitting your article check the Instructions for Authors carefully.

The corresponding author should be prepared to collect documentation of compliance with ethical standards and send if requested during peer review or after publication.

The Editors reserve the right to reject manuscripts that do not comply with the above-mentioned guidelines. The author will be held responsible for false statements or failure to fulfill the above-mentioned guidelines.

Disclosure of Potential Conflicts of Interest

Authors must disclose all relationships or interests that could have direct or potential influence or impart bias on the work. Although an author may not feel there is any conflict, disclosure of relationships and interests provides a more complete and transparent process, leading to an accurate and objective assessment of the work. Awareness of a real or perceived conflicts of interest is a perspective to which the readers are entitled. This is not meant to imply that a financial relationship with an organization that sponsored the research or compensation received for consultancy work is inappropriate. Examples of potential conflicts of interests that are directly or indirectly related to the research may include but are not limited to the following:
• Research grants from funding agencies (please give the research funder and the grant number)
• Honoraria for speaking at symposia
• Financial support for attending symposia
• Financial support for educational programs
• Employment or consultation
• Support from a project sponsor
• Position on advisory board or board of directors or other type of management relationships
• Multiple affiliations
• Financial relationships, for example equity ownership or investment interest
• Intellectual property rights (e.g. patents, copyrights and royalties from such rights)
• Holdings of spouse and/or children that may have financial interest in the work

In addition, interests that go beyond financial interests and compensation (non-financial interests) that may be important to readers should be disclosed. These may include but are not limited to personal relationships or competing interests directly or indirectly tied to this research, or professional
interests or personal beliefs that may influence your research. The corresponding author collects the conflict of interest disclosure forms from all authors. In author collaborations where formal agreements for representation allow it, it is sufficient for the corresponding author to sign the disclosure form on behalf of all authors. Examples of forms can be found here: http://www.springer.com/life+sciences/cell+biology/journal/13577

The corresponding author will include a summary statement in the text of the manuscript in a separate section before the reference list, that reflects what is recorded in the potential conflict of interest disclosure form(s).

See below examples of disclosures:

**Funding:** This study was funded by X (grant number X).

**Conflict of Interest:** Author A has received research grants from Company A. Author B has received a speaker honorarium from Company X and owns stock in Company Y. Author C is a member of committee Z.

If no conflict exists, the authors should state:

Conflict of Interest: The authors declare that they have no conflict of interest.

### Research involving human participants and/or animals

1) **Statement of human rights**

When reporting studies that involve human participants, authors should include a statement that the studies have been approved by the appropriate institutional and/or national research ethics committee and have been performed in accordance with the ethical standards of the institutional and/or national research committee or institutional review board explicitly approved the doubtful aspects of the study.

The following statements should be included in the text before the References section:

**Ethical approval:** “All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.”

For retrospective studies, please add the following sentence:

“For this type of study formal consent is not required.”

2) **Statement on the welfare of animals**

The welfare of animals used for research must be respected. When reporting experiments on animals, authors should indicate whether the international, national, and/or institutional guidelines for the care and use of animals have been followed, and that the studies have been approved by a research ethics committee at the institution or practice at which the studies were conducted (where such a committee exists).

For studies with animals, the following statement should be included in the text before the References section:

**Ethical approval:** “All applicable international, national, and/or institutional guidelines for the care and use of animals were followed.”

If applicable (where such a committee exists): “All procedures performed in studies involving animals were in accordance with the ethical standards of the institution or practice at which the studies were conducted.”

If articles do not contain studies with human participants or animals by any of the authors, please select one of the following statements:

“This article does not contain any studies with human participants performed by any of the authors.”

“This article does not contain any studies with animals performed by any of the authors.”

“This article does not contain any studies with human participants or animals performed by any of the authors.”

### Informed Consent

All individuals have individual rights that are not to be infringed. Individual participants in studies have, for example, the right to decide what happens to the (identifiable) personal data gathered, to what they have said during a study or an interview, as well as to any photograph that was taken. Hence it is important that all participants gave their informed consent in writing prior to inclusion in the study. Identifying details (names, dates of birth, identity numbers and other information) of the participants that were studied should not be published in written descriptions, photographs, and genetic profiles unless the information is essential for scientific purposes and the participant (or parent or guardian if the participant is incapable) gave written informed consent for publication. Complete anonymity is difficult to achieve in some cases, and informed consent should be obtained if there is any doubt. For example, masking the eye region in photographs of participants is inadequate protection of anonymity. If identifying characteristics are altered to protect anonymity, such as in genetic profiles, authors should provide assurance that alterations do not distort scientific meaning.

The following statement should be included:

**Informed consent:** “Informed consent was obtained from all individual participants included in the study.”

If identifying information about participants is available in the article, the following statement should be included:

“Additional informed consent was obtained from all individual participants for whom identifying information is included in this article.”

### After Acceptance

Upon acceptance of your article you will receive a link to the special Author Query Application at Springer’s web page where you can sign the Copyright Transfer Statement online and indicate whether you wish to order Open Choice or offprints. Once the Author Query Application has been completed, your article will be processed and you will receive the proofs.

### Open Choice

In addition to the normal publication process (whereby an article is submitted to the journal and access to that article is granted to customers who have purchased a subscription), Springer provides an alternative publishing option: Springer Open Choice. A Springer Open Choice article receives all the...
benefits of a regular subscription-based article, but in addition is made available publicly through Springer’s online platform SpringerLink. We regret that Springer Open Choice cannot be ordered for published articles. For details, see Springer Open Choice [http://springer.com/openchoice]

Copyright Transfer
Authors will be asked to transfer copyright of the article to the Japan Human Cell Society and the Publisher (or grant the Publisher exclusive publication and dissemination rights). This will ensure the widest possible protection and dissemination of information under copyright laws. Open Choice articles do not require transfer of copyright as the copyright remains with the author. In opting for open access, they agree to the Springer Open Choice License.

Offprints
Offprints can be ordered by the corresponding author.

Color Illustrations
Publication of color illustrations is free of charge.

Proof Reading
Authors are informed by e-mail that a temporary URL has been created from which they can obtain their proofs. The purpose of the proof is to check for typesetting or conversion errors and the completeness and accuracy of the text, tables and figures. Substantial changes in content, e.g., new results, corrected values, title and authorship, are not allowed without the approval of the Editor.

Online First
The article will be published online after receipt of the corrected proofs. This is the official first publication citable with the DOI. After online publication, further changes can only be made in the form of an Erratum, which will be hyperlinked to the article. After release of the online issue, the article can also be cited by issue and page numbers.